Meeting of the Trust Board 26 September 2012 AGENDA
Total Page：16
File Type：pdf, Size：1020Kb
Meeting of the Trust Board 26th September 2012 Dear Members There will be a public meeting of the Trust Board on Wednesday 26th September 2012 commencing at 2:30pm in the Charles West Room, Paul O’Gorman Building, Great Ormond Street, London, WC1N 3JH. Company Secretary Direct Line: 020 7813 8230 Fax: 020 7813 8218 AGENDA Agenda Item Presented by Authors STANDARD ITEMS 1. Apologies for absence Chair Declarations of Interest The Chair and members of this meeting are reminded that if they have any pecuniary interest, direct or indirect, in any contract, proposed or other matter which is the subject of consideration at this meeting, they must, as soon as practicable after the commencement of the meeting disclose that fact and not take part in the consideration or discussion of the contract, proposed contract or other matter, nor vote on any questions with respect to it. 2. Minutes of Meeting held on 25th July 2012 Chair J 3. Matters Arising / Action point checklist Chair K 4. Chief Executive’s Update Chief Executive (Interim) Y 5. Clinical Presentation (Endocrinology) Professor Mehul Dattani, L Specialty Lead 6. Quality, Safety & Transformation Update including Co-Medical Director (ME) M update on Theatre Utilisation Improvement FOR APPROVAL 7. Assurance and Escalation Framework Company Secretary O UPDATES 8. Performance Report (August 2012) Acting Chief Operating P Officer 9. Finance and Activity Report (five months to 31st Chief Finance Officer Q August 2012) 10. Management Board Effectiveness Review Company Secretary R 11. NHSLA Update Acting Chief Operating S Officer FOR RATIFICATION 12. Consultant Appointments Chair Verbal FOR INFORMATION 13. Members’ Council – Update from July and August Chairman T 2012 meeting 14. Clinical Governance Committee update (July 2012) Ms Mary MacLeod, Chair U of the Clinical Governance Committee/ Company Secretary 15. Final Management Board minutes (July and August Company Secretary W 2012) 16. Key Monitor Correspondence Acting Chief Operating Z Officer 17. Any Other Business (Please note that matters to be raised under any other business should be notified to the Company Secretary before the start of the Board meeting.) 18. Next meeting The next Trust Board meeting will be held on Wednesday 28th November 2012 in the Charles West Room, Level 2, Paul O’Gorman Building, Great Ormond Street, London, WC1N 3JH. ATTACHMENT J Attachment J DRAFT Minutes of the meeting of Trust Board held on 25th July 2012 Present Baroness Tessa Blackstone Chairman Ms Yvonne Brown Non-Executive Director Dr Barbara Buckley Co-Medical Director Professor Andy Copp Non-Executive Director Dr Jane Collins Chief Executive Professor Martin Elliott Co-Medical Director Mr David Lomas Non-Executive Director Ms Mary MacLeod Non-Executive Director Mrs Liz Morgan Chief Nurse and Director of Education Mrs Claire Newton Chief Finance Officer Mr John Ripley Non-Executive Director Mr Charles Tilley Non-Executive Director In attendance Dr Anna Ferrant Company Secretary Miss Victoria Goddard Trust Board Administrator (minutes) Professor David Goldblatt Director of Clinical Research and Innovation Dr John Hartley Consultant Microbiologist and DIPC Ms Deirdre Malone Deputy DIPC Mr Stuart Player Public Councillor *Denotes a person who was present for part of the meeting 509 Apologies for absence 509.1 Apologies for absence were received from Ms Fiona Dalton, Chief Operating Officer. 510 Declarations of interest 510.1 No declarations of interest were received. 511 Minutes 511.1 403.6 – It was agreed that an update on this action would be brought to the next Trust Board meeting in September. 511.2 The minutes were approved with no amendments. 512 Matters arising and action checklist 512.1 Minute 443.4 – Professor Martin Elliott, Co-Medical Director reported that the Clinical Governance Committee was being fully updated on the Trust’s 25th July 2012 Great Ormond Street Hospital for Children NHS Foundation Trust –Trust Board DRAFT minutes 1 Attachment J progress with NHSLA. He confirmed that the level three assessment would take place in the Autumn and work would be closely monitored by the Quality and Safety Committee and Clinical Governance Committee. 512.2 Ms Mary MacLeod reported that the Clinical Governance Committee had received an encouraging report at its last meeting. 512.3 Mrs Liz Morgan, Chief Nurse and Director of Education expressed some concern that staff being released to work on NHSLA would impact external assessments and CQUIN achievement. Minute 482.16 – It was agreed that the Baroness Blackstone would hold an 512.4 informal meeting with members of the Neurodisability team. 513 Chief Executive Update 513.1 Safe and Sustainable 513.2 Dr Jane Collins, Chief Executive reported that the decision around Paediatric Cardiac Surgery Centres had been made on 4th July 2012. She confirmed that commissioners had expressed a wish to continue to move forward with the original decision despite the reservations of a number of centres. 513.3 Professor Martin Elliott, Co-Medical Director reported that the Cardiac site in Leeds which had been decommissioned had requested that the decision be reconsidered in light of additional ECMO specialists being employed at the centre. He confirmed that Leeds would contact the Health Overview and Scrutiny Committee. 513.4 Dr Collins confirmed that a group, chaired by Dr Andrew Mitchell, Medical Director of NHS London had been established to discuss implementation. The group would be attended by Dr Collins or Ms Fiona Dalton. 513.5 Director of Redevelopment Role 513.6 Dr Collins confirmed that negotiations were on-going to appoint a Director of Redevelopment. She added that Natalie Robinson, Deputy Director of Redevelopment would be acting up into the role. 513.7 Dr Collins reported that the 2B Business Case would be submitted to Monitor for consideration at their August meeting. She confirmed that Monitor were aware that the Trust did not yet have a signed finance agreement and proposed that momentum on 2B was maintained and plans were considered at the next Finance and Investment Committee meeting. 513.8 Ms Claire Newton, Chief Finance Officer confirmed that the Trust Board would be required to sign a Governance Statement. She added that Monitor was seeking legal advice as to whether it was appropriate to review the 2B business case before the completion of procurement. She added that if it was not considered, £13m would be spent at risk prior to procurement completion. 513.9 Olympic Planning 25th July 2012 Great Ormond Street Hospital for Children NHS Foundation Trust –Trust Board DRAFT minutes 2 Attachment J 513.10 Dr Collins confirmed that preparations were in hand for service provision during the Olympics. She reported that the cardiac wing was being used as additional storage and accommodation was being made available for families. 513.11 Dr Collins reported that departments had noted a greater number of families cancelling appointments during the Olympics, possibly due to worries about travel in London. Baroness Blackstone suggested that the Trust was proactive in sending 513.12 information to families requesting that appointments were kept. 513.13 The Trust Board noted the update. 514 Quality, Safety and Transformation Update 514.1 Professor Martin Elliott reported that there had been no adverse changes in the period since the last report other than a minor increase in the number of Serious Incidents. 514.2 He reported that work was on-going on the benchmarking project to confirm GOSH’s position as one of the top five children’s hospitals in the world. 514.3 It was confirmed that letters of agreement had been received from all competitors who had been approached to take part in the benchmarking exercise. Baroness Blackstone asked why there had been a delay in publishing clinical 514.4 outcome measure positions on the GOSH website. Dr Collins reported that the Members’ Council had provided feedback that 514.5 the information was not accessible and asked that it was presented in a different way. The Board noted the update. 514.6 515 Revised Trust Board Terms of Reference 515.1 Dr Anna Ferrant, Company Secretary reported that the Terms of Reference for the Board were being reviewed due to NHSLA requirements. 515.2 She confirmed that reporting and monitoring arrangements must be reference as well as the minimum number of meetings to be attended by Directors. 515.3 The following amendments were agreed: Directors’ expected attendance to be reduced to 7 meetings per year Section 5 to read ‘Directors are expected to attend…’ The Company Secretary to be removed from the list of Directors who were entitled to remain during confidential business 25th July 2012 Great Ormond Street Hospital for Children NHS Foundation Trust –Trust Board DRAFT minutes 3 Attachment J The Terms of Reference were ratified subject to the above amendments. 515.4 516 Infection Control Report including Annual DIPC Report 516.1 Ms Deidre Malone, Deputy DIPC reported that each Clinical Unit now had an infection control structure in place. 516.2 It was reported that a rise in infection rates continued to impact the Trust in terms of patient flow, however from four cases of MRSA reported in 2011-12, it had been confirmed that only one case would have been preventable. 516.3 Discussion took place around the need to ensure enough staff were present to enable robust infection surveillance. 516.4 The Board was informed that modelling was being conducted to determine the costs of different methods of infection surveillance. Management Board would review these costings and agree a way forward. The Trust Board approved the Infection Prevention and Control action plan. 516.5 517 Update with progress on research strategy and UCLP research 517.1 Professor David Goldblatt, Director of Clinical Research and Development reported that funding was awarded for a Biomedical Research Centre in Summer 2012 and as a result, amendments had been made to the research strategy.